Wellmarker Bio introduced Medidata’s Rave Study Feasibility and Rave EDC solution for its lead asset WM-S1(Colon cancer treatment)’s global phase 1 study.
* Rave Study Feasibility: A solution providing the best-performing site facilities
* Rave EDC: An integrated data solution
The company plans to conduct clinical trials in Australia, Korea and United states. By leveraging Medidata’s solution, Wellmarker Bio successfully selected clinical sites in Australia and submitted the protocol to the Institutional Review Boards(IRB). “Through Medidata’s solution that can predict the patient recruitment rate of each institution, we were able to initiate clinical trials faster and more efficiently even in the Covid-19 crisis ”cited Dong-Hoon Jin, CEO of Wellmarker Bio.
Wellmarker Bio is the first spin-off company from Asan Medical center, established in December 22, 2016. It is developing 9 first-in-class anticancer drugs based on predictive biomarkers. One of the lead assets WM-S1, a small molecule targeting Erbitux-resistant patients, is funded by Korea Drug Development(KDDF) and is about to initiate global phase 1 study with Covance.
Please click on the link below to read the full news in Korean